1)Tashiro Y, et al:Drug-induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms due to lamotrigine differs from that due to other drugs. J Dermatol 46:226-233, 2019
2)橋本公二.重症多形滲出性紅斑(SJS),中毒性表皮壊死症(TEN),薬剤性過敏症症候群(DIHS)の診断基準2005の作成.厚生労働科学研究費補助金難治性疾患克服研究事業 難治性皮膚疾患〔重症多形滲出性紅斑(急性期)を含む〕の画期的治療法に関する研究.橋本公二.平成17年度総括・分担研究報告書(厚生労働科学研究成果データベース) https://mhlw-grants.niph.go.jp/system/files/2005/057141/200500880A/200500880A0001.pdf(2023年8月閲覧)
3)渡邉裕子:発疹タイプ別の薬疹の診かたと対応.阿部理一郎(編):目で見て役立つ 薬疹の上手な診かた・対応ガイド,pp 78-83,診断と治療社,2022
4)Watanabe T, et al:Mortality and risk factors on admission in toxic epidermal necrolysis;A cohort study of 59 patients. Allergol Int 70:229-234, 2021
5)Shiohara T, Mizukawa Y:Drug-induced hypersensitivity syndrome(DiHS)/drug reaction with eosinophilia and systemic symptoms(DRESS);An update in 2019. Allergol Int 68:301-308, 2019
6)Mizukawa Y, et al:Drug-induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms severity score;A useful tool for assessing disease severity and predicting fatal cytomegalovirus disease. J Am Acad Dermatol 80:670-678, 2019
7)Kitamura K, et al:Relationship among human herpesvirus 6 reactivation, serum interleukin 10 levels, and rash/graft-versus-host disease after allogeneic stem cell transplantation. J Am Acad Dermatol 58:802-809, 2008
8)Yamaguchi Y:Exploring the deeper linkage between adverse drug reactions and autoimmune diseases. Allergol Int 71:161-162, 2022
9)Tohyama M, et al:Influence of corticosteroid therapy on viral reactivation in drug-induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms. J Dermatol 47:476-482, 2020
10)Mizukawa Y, et al:Risk of progression to autoimmune disease in severe drug eruption;Risk factors and the factor-guided stratification. J Invest Dermatol 142:960-968, 2022